Xencor Inc Market Cap ($827.65 Million)
Market Cap & Net Worth: Xencor Inc (XNCR)
Xencor Inc market cap. Xencor Inc (NASDAQ:XNCR) has a market capitalization of $827.65 Million ($827.65 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9359 globally and #2644 in its home market, demonstrating a 15.40% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xencor Inc's stock price $29.82 by its total outstanding shares 71410469 (71.41 Million). Also see Xencor Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Xencor Inc Market Cap History (2015–2026)
Xencor Inc market cap history from 2015 to 2026. Data shows growth from $1.04 Billion to $2.13 Billion (8.44% CAGR). Check XNCR stock price for real-time trading data and today's change.
Index Memberships
Xencor Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.03% | #271 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #1004 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.04% | #159 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.56 Trillion | 0.05% | #494 of 602 |
Weight: Xencor Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Xencor Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xencor Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Xencor Inc equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
14.85x
Xencor Inc's market cap is 14.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.04 Billion | $27.76 Million | -$17.59 Million | 37.61x | N/A |
| 2016 | $1.88 Billion | $87.52 Million | $23.62 Million | 21.48x | 79.56x |
| 2017 | $1.57 Billion | $35.71 Million | -$48.92 Million | 43.83x | N/A |
| 2018 | $2.58 Billion | $40.60 Million | -$70.41 Million | 63.60x | N/A |
| 2019 | $2.46 Billion | $156.70 Million | $26.88 Million | 15.67x | 91.38x |
| 2020 | $3.12 Billion | $122.69 Million | -$63.54 Million | 25.39x | N/A |
| 2021 | $2.86 Billion | $275.11 Million | $82.63 Million | 10.41x | 34.67x |
| 2022 | $1.86 Billion | $164.58 Million | -$55.18 Million | 11.30x | N/A |
| 2023 | $1.52 Billion | $168.34 Million | -$126.09 Million | 9.01x | N/A |
| 2024 | $1.64 Billion | $110.49 Million | -$232.62 Million | 14.85x | N/A |
Competitor Companies of XNCR by Market Capitalization
Companies near Xencor Inc in the global market cap rankings as of November 1, 2026. Also see balance sheet size of Xencor Inc for a full breakdown of the balance sheet.
Key companies related to Xencor Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Xencor Inc (2015–2026)
Market capitalization of Xencor Inc from 2015 to today. Between 2015 and today, Xencor Inc's market cap moved from $1.04 Billion to $ 2.13 Billion, with a yearly change of 8.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.13 Billion | +94.77% |
| 2025 | $1.09 Billion | -33.38% |
| 2024 | $1.64 Billion | +8.24% |
| 2023 | $1.52 Billion | -18.47% |
| 2022 | $1.86 Billion | -35.09% |
| 2021 | $2.86 Billion | -8.04% |
| 2020 | $3.12 Billion | +26.87% |
| 2019 | $2.46 Billion | -4.89% |
| 2018 | $2.58 Billion | +64.96% |
| 2017 | $1.57 Billion | -16.72% |
| 2016 | $1.88 Billion | +80.03% |
| 2015 | $1.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Xencor Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $827.65 Million USD |
| MoneyControl | $827.65 Million USD |
| MarketWatch | $827.65 Million USD |
| marketcap.company | $827.65 Million USD |
| Reuters | $827.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for t… Read more